Mentor Capital Inc. - Comparable Companies

Mentor Capital, Inc and CI Companies

66 Days Left on $1 Call

About Mentor Capital MNTR - QI Relationship About MNTR Summary Data Management Team Professional Support Philosophy Ethics Corporate Governance The Investor's Corner Current Financials w/QI 2008 Audit w/o QI 15(c) 2-11 Comparable Companies Analysts' Coverage $5 / Share - Sr. Securities Analyst $28 / Share by 2012, BioMed Reports Medical Trials & Publications FDA Trials Early Results Medical Publications Visit Portfolio Companies

MNTR In The Cancer Immunotherapy Index

Bookmark This Page

Cancer Immunotherapy Index

PDF Document Click to see larger

Home

Chairman's Letters

◦ Welcome to the Team Leading the Cancer Fight

◦ Chairman's 2009 Recap with $0.91/sh Portfolio Gains

◦ List of All Releases

◦ MNTR Invests in 10 Cancer Index Companies

◦ MNTR Retains Investment Bank to Assist Roll Out Cancer Immunotherapy Index Fund

◦ 2010 Actively Managed Cancer Immunotherapy Index Announced by MNTR

◦ University Agreement Indicates Broad Cancer Application for QI Treatment

◦ New Lab, Filings and JV Talks

◦ MNTR Presents In NYC

◦ MNTR Leads Cancer Index

◦ Start of FDA Trials

◦ QI Announces MNTR

◦ MNTR Acquires First 20% of QI

◦ MNTR Calls $3 Million Tranche

◦ MNTR Initiates Trading

MNTR In The News

◦ All News Articles

◦ Mentor Capital Update in Seeking Alpha

◦ MNTR Top Gainer in Cancer Index

◦ MNTR Stealth Cancer Play

◦ MNTR Forecast at $28.60 in 2012

◦ Quantum Leap In Funding

Cancer Resources

Information For Brokers

Shareholder Updates

FAQ

All PDF documents will open a new browser window

©2009 Mentor Capital Inc. | All Rights Reserved

Safe Harbor Statement Site Map